Full text is available at the source.
Abstract
Frailty is associated with weaker or less durable responses to COVID-19 lipid nanoparticle mRNA vaccines compared to non-frail individuals.
- Frailty can lead to increased vulnerability to infection and impaired vaccine response.
- Alterations in blood cell production, chronic inflammation, and immune system dysfunction are linked to frailty-related immunosenescence.
- Evidence suggests that people with frailty may show heterogeneous responses to vaccination.
- Lipid nanoparticle mRNA vaccines offer opportunities for customization to better suit individuals with frailty.
- Optimizing vaccine components and addressing comorbidities and nutrition may improve vaccination outcomes for older adults.
Simplified